Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190

1.

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Gage BF, Lesko LJ.

J Thromb Thrombolysis. 2008 Feb;25(1):45-51. Epub 2007 Oct 1. Review.

PMID:
17906972
[PubMed - indexed for MEDLINE]
2.

Pharmacogenetics-based coumarin therapy.

Gage BF.

Hematology Am Soc Hematol Educ Program. 2006:467-73. Review.

PMID:
17124101
[PubMed - indexed for MEDLINE]
Free Article
3.

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.

Gulseth MP, Grice GR, Dager WE.

Am J Health Syst Pharm. 2009 Jan 15;66(2):123-33. doi: 10.2146/ajhp080127. Review.

PMID:
19139476
[PubMed - indexed for MEDLINE]
4.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
[PubMed - indexed for MEDLINE]
5.

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.

King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS, Eby C.

Am J Clin Pathol. 2008 Jun;129(6):876-83. doi: 10.1309/1E34UAPR06PJ6HML.

PMID:
18480003
[PubMed - indexed for MEDLINE]
Free Article
6.

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.

Miao L, Yang J, Huang C, Shen Z.

Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. Epub 2007 Sep 27.

PMID:
17899045
[PubMed - indexed for MEDLINE]
7.

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.

Siguret V, Pautas E, Gouin-Thibault I.

Vitam Horm. 2008;78:247-64. doi: 10.1016/S0083-6729(07)00012-X. Review.

PMID:
18374198
[PubMed - indexed for MEDLINE]
8.

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Yin T, Miyata T.

Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11. Review.

PMID:
17161452
[PubMed - indexed for MEDLINE]
9.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
[PubMed - indexed for MEDLINE]
10.

[Warfarin resistance and related pharmacogenetic information].

Takahashi H.

Brain Nerve. 2008 Nov;60(11):1365-71. Review. Japanese.

PMID:
19069171
[PubMed - indexed for MEDLINE]
11.

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P.

PLoS Genet. 2009 Mar;5(3):e1000433. doi: 10.1371/journal.pgen.1000433. Epub 2009 Mar 20.

PMID:
19300499
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL.

Thromb Haemost. 2004 Jan;91(1):87-94.

PMID:
14691573
[PubMed - indexed for MEDLINE]
13.

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T.

Thromb Res. 2007;120(2):181-6. Epub 2006 Oct 17.

PMID:
17049586
[PubMed - indexed for MEDLINE]
14.

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Scott SA, Edelmann L, Kornreich R, Desnick RJ.

Am J Hum Genet. 2008 Feb;82(2):495-500. doi: 10.1016/j.ajhg.2007.10.002. Epub 2008 Jan 17.

PMID:
18252229
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Genetic influences on the response to warfarin.

Kamali F.

Curr Opin Hematol. 2006 Sep;13(5):357-61. Review.

PMID:
16888441
[PubMed - indexed for MEDLINE]
16.

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].

Benusiglio PR, Desmeules J, de Moerloose P, Dayer P.

Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. Review. French.

PMID:
17955831
[PubMed - indexed for MEDLINE]
17.

Building individualized medicine: prevention of adverse reactions to warfarin therapy.

Krynetskiy E, McDonnell P.

J Pharmacol Exp Ther. 2007 Aug;322(2):427-34. Epub 2007 May 11.

PMID:
17496169
[PubMed - indexed for MEDLINE]
Free Article
18.

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.

Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller-Reible C, Watzka M.

Thromb Haemost. 2007 Sep;98(3):570-8. Review.

PMID:
17849045
[PubMed - indexed for MEDLINE]
19.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
[PubMed - indexed for MEDLINE]
20.

Overview of pharmacogenetics in anticoagulation therapy.

Hill CE, Duncan A.

Clin Lab Med. 2008 Dec;28(4):513-24. doi: 10.1016/j.cll.2008.09.002. Review.

PMID:
19059059
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk